Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02935140
Other study ID # 2015-09
Secondary ID
Status Completed
Phase N/A
First received October 13, 2016
Last updated November 18, 2016
Start date December 2015
Est. completion date June 2016

Study information

Verified date November 2016
Source St Mary's Hospital for Children
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

Many children who are born medically fragile due to prematurity, multiple congenital abnormalities or an acquired insult (i.e. cardiac, neurologic, etc.) may require tracheostomy tube placement due to need of chronic respiratory support. Patients on tracheostomy tubes are often unable to vocalize, causing a delay in speech development and poor speech. To help restore normal phonation and promote language development in young pediatric patients with tracheostomies, speaking valves are used. Previously it was shown that the Passy-Muir speaking valve was safe to use during sleep in children by showing there were no adverse cardiopulmonary events seen. One objective measurement that was not evaluated was trans-tracheal pressure manometry. The purpose of this study is to continue to validate the safety of the Passy-Muir speaking valve while asleep, with the use of trans-tracheal manometry by comparing expiratory pressure manometry while the patient is awake and asleep.


Description:

Previously it was shown that the Passy-Muir speaking valve was safe to use during sleep in children. There were no adverse cardiopulmonary events seen while wearing the speaking valve during sleep. However, trans-tracheal pressure was not measured while these children were asleep wearing the Passy-Muir speaking valve.The investigators hypothesize that patients who tolerate speaking valve while awake will have similar trans-tracheal pressure measurement when asleep as when they are awake.

The specific aims of this proposal are:

1) to show that the Passy-Muir speaking valve worn during sleep has similar trans-tracheal pressure manometry as when worn while awake.

The primary outcome measure is to show that trans-tracheal manometry measurement is similar while on the Passy-Muir speaking valve when patients are awake and asleep

Secondary outcomes are a) recording of symptoms (i.e. choking, gagging, increased respiratory rate, abnormal breathing pattern, coughing, chest tightness and aversion) while wearing the speaking valve either awake or asleep b) recording vital signs which will be compared to normal and baseline for age (i.e. heart rate, respiratory rate, end-tidal carbon dioxide and oxygen saturation) while awake and asleep.

Background and significance:

Previously it was shown that Passy-Muir speaking valve is safe to use during sleep in children. However it continues to be contraindicated for use while asleep. A small prospective study done on 10 tracheostomized adult patients with a mean age of 70 years showed that the use of the speaking valve for one night in seriously ill patients was not associated with apneas or significant desaturations. A cohort study of 32 tracheostomized patients showed that 14 patients were able to tolerate speaking valve for 24 hours; even during sleep.

Pediatric patients with tracheostomy tube are often unable to vocalize. Tracheostomy tubes allow the exhaled flow of air to bypass the vocal cords out through the opening of the tube making speech difficult. This causes a delay in speech development and poor speech. Speaking valves, like the Passy-Muir valve, restore normal phonation and promote language development in young pediatric patients with tracheostomies. Speech development is not the only benefit seen with speaking valves. Speaking valves can lead to improvement in swallowing safety reducing aspiration, improved ventilator weaning leading to more rapid tracheal decannulation, reduce secretion management, improve hygiene, and enhance smell and taste.

Evaluation of speaking valve tolerance can be done by monitoring vital signs (i.e. respiratory rate, heart rate, and oxygen saturation). In addition, measurement of trans-tracheal pressure is an invaluable tool in evaluating subjects for speaking valve placement. Measurement of trans-tracheal pressure is predictive of good tolerance of the valve.

The measurement allows one to quickly and easily assess patency of the upper airway and the ability to force air through the vocal cords. If the pressures are elevated, greater than 10 cm of water on inhalation phase and 30cm of water on the exhalation phase, it would indicate an obstruction in the upper part of the trachea (i.e. subglottic stenosis). The pressures can also evaluate respiratory function prior to considering patients for placement of the valve.

Many children who are born medically fragile due to prematurity, multiple congenital abnormalities or an acquired insult (i.e. cardiac, neurologic, etc.) may require tracheostomy tube placement due to need of chronic respiratory support. Initially, after a patient is assessed for a speaking valve and is cleared for use, a patient may be apprehensive toward the speaking valve.

If a patient displays discomfort, anxiety, dyspnea/respiratory distress or there is air trapping (from the build-up of subglottic pressure from incomplete exhalation) trials are repeated on subsequent days. However, one can assume that initial failure is due to aversion, but it may be due to resistance in the upper airway, or vice versa.

The purpose of this study is to continue to validate the safety of the Passy-Muir speaking valve while asleep, with the use of trans-tracheal manometry by comparing expiratory pressure manometry while the patient is awake and asleep.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender Both
Age group 1 Month to 18 Years
Eligibility Inclusion Criteria:

i. Any subject between the ages of 0-18 years of age who is a resident of St Mary's Healthcare System for Children with a chronic tracheostomy may be enrolled. Patients have to be approved for a Passy-Muir speaking valve as per St Mary's Healthcare System for Children written policy.

Exclusion Criteria:

i. Patients who do not meet the criteria for the use of speaking valve (i.e. unconscious and/or comatose patients, patients who require 24-hour inflated tracheostomy tube cuff due to inadequate ventilation, foam-filled tracheostomy tube, severe airway obstruction, unmanageable thick secretions, severe risk for aspiration, severely reduced lung elasticity, and not intended for use with endotracheal tubes).

ii. Patients with an acute illness and is not at baseline status. iii. Have any kind of respiratory distress.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
St Mary's Hospital for Children

References & Publications (5)

Barraza GY, Fernandez C, Halaby C, Ambrosio S, Simpser EF, Pirzada MB. The safety of tracheostomy speaking valve use during sleep in children: a pilot study. Am J Otolaryngol. 2014 Sep-Oct;35(5):636-40. doi: 10.1016/j.amjoto.2014.04.011. — View Citation

Brigger MT, Hartnick CJ. Drilling speaking valves: a modification to improve vocalization in tracheostomy dependent children. Laryngoscope. 2009 Jan;119(1):176-9. doi: 10.1002/lary.20077. — View Citation

Buckland A, Jackson L, Ilich T, Lipscombe J, Jones G, Vijayasekaran S. Drilling speaking valves to promote phonation in tracheostomy-dependent children. Laryngoscope. 2012 Oct;122(10):2316-22. doi: 10.1002/lary.23436. — View Citation

Hopkins C, Whetstone S, Foster T, Blaney S, Morrison G. The impact of paediatric tracheostomy on both patient and parent. Int J Pediatr Otorhinolaryngol. 2009 Jan;73(1):15-20. doi: 10.1016/j.ijporl.2008.09.010. — View Citation

Johnson DC, Campbell SL, Rabkin JD. Tracheostomy tube manometry: evaluation of speaking valves, capping and need for downsizing. Clin Respir J. 2009 Jan;3(1):8-14. doi: 10.1111/j.1752-699X.2008.00100.x. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Trans-tracheal Pressure Measurement trans-tracheal manometry measurement is similar while on the Passy-Muir speaking valve when patients are awake and asleep one day Yes
Secondary Recording of symptoms a) recording of symptoms (i.e. choking, gagging, increased respiratory rate, abnormal breathing pattern, coughing, chest tightness and aversion) while wearing the speaking valve either awake or asleep one day Yes
Secondary vital signs b) recording vital signs which will be compared to normal and baseline for age (i.e. heart rate, respiratory rate, end-tidal carbon dioxide and oxygen saturation) while awake and asleep. one day Yes
See also
  Status Clinical Trial Phase
Completed NCT05084976 - Parental Perception of COVID-19 Vaccine in Technology Dependent Patients
Not yet recruiting NCT05756387 - Improving Chronic Nocturnal Noninvasive Ventilation: a Multimodality Approach
Enrolling by invitation NCT04208581 - Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure Phase 3
Recruiting NCT02260583 - Effect of Extracorporeal CO2 Removal in Stable Hypercapnic COPD Patients N/A
Completed NCT01255111 - Adaptation to Nocturnal Noninvasive Ventilation in Patients With Chronic Respiratory Failure (ROOMILA) N/A
Active, not recruiting NCT03499470 - Structured Discharge and Follow-up Protocol for COPD Patients Receiving LTOT and NIV N/A
Completed NCT04143230 - Identification of In-hospital Patients in Need of Palliative Care Using a New Simplified Screening Tool N/A
Terminated NCT00208078 - Effect of Non-Invasive Ventilation in Cystic Fibrosis Patient With Chronic Respiratory Failure. Phase 4
Recruiting NCT06286917 - Initiation of Noninvasive Ventilation in ALS Patients With Chronic Respiratory Insufficiency N/A
Completed NCT02342899 - Cost Effectiveness of Outpatient Set-up of Automated NIV in Obese Patients With Chronic Respiratory Failure Phase 3
Terminated NCT03473171 - Implementation of Nasal Non-Invasive Ventilation With a RAM Cannula in the Inpatient /Outpatient Setting N/A
Not yet recruiting NCT05258370 - Fibroblast Growth Factor 23 in Chronic Respiratory Failure
Completed NCT02804243 - The Efficacy of Nasal High Flow Oxygen Therapy With Rehabilitation in the Patients With Chronic Respiratory Failure N/A
Completed NCT01479959 - Impact of Patient Controlled Positive End-expiratory Pressure on Speech in Tracheostomized Ventilated Patients N/A
Completed NCT01090986 - Home Mechanical Ventilation Effectiveness and Air Leaks N/A
Completed NCT00698958 - Ambulatory Adaptation to Non-Invasive Mechanical Ventilation Phase 4
Not yet recruiting NCT06119087 - Mechanical Insufflation in the Philadelphia Amyotrophic Lateral Sclerosis Cohort (MI-PALS) Study N/A
Recruiting NCT05796297 - Clinical Impact of Patient-ventilator Asynchrony
Recruiting NCT04481295 - Study on Optimal Oxygen Concentration During Pulmonary Rehabilitation N/A
Withdrawn NCT05379439 - Family Connections N/A